66521-66-2Relevant articles and documents
Navigating into the chemical space between MGCD0103 and SAHA: Novel histone deacetylase inhibitors as a promising lead
Zhang, Xin,Lv, Peng-Cheng,Li, Dong-Dong,Zhang, Wei-Ming,Zhu, Hai-Liang
, p. 1816 - 1825 (2015)
Histone deacetylase inhibitors (HDIs) are an increasingly important class of cancer-targeting agents. Two kinds of small molecule histone deacetylase inhibitors, mainly employing the motifs of the two known HDAC inhibitors MGCD0103 and SAHA as the basic scaffolds, were designed, synthesized and evaluated for the preliminary biological activity. Strikingly, these two compounds regained a long half-life potency like MGCD0103 and retained the non-selectivity for HDAC1 versus HDAC6 derived from SAHA. Together, these two compounds combining both the advantages of MGCD0103 and SAHA could be considered as novel histone deacetylase inhibitors in targeted drug development and possibly anticipated to be more effective under the clinical trials.
Computer Modeling and Synthesis of Potential Inhibitors of Tyrosine Kinase BCR-ABL with the T315I Mutation
Fedarkevich, A. N.,Sharko, O. L.,Shmanai, V. V.
, p. 187 - 198 (2020/05/04)
Abstract—: A comparative analysis of the interaction of the chimeric protein BCR-ABL, of the normal type and with the T315I mutation, with known inhibitors as well as compounds potentially capable of inhibiting the mutant protein has been carried out by computer modeling. It has been shown that the compounds proposed are incorported into the structure of the protein with the retention of the basic hydrogen bonds and intermolecular interactions. Two structures containing the pyrrole cycle have been synthesized, which, according to the results of computer modeling, appear to be most promising.
Smo inhibitor as well as synthesis method and application thereof
-
Paragraph 0044; 0052-0056, (2019/09/17)
The invention discloses an Smo inhibitor as well as a synthesis method and application thereof. A structural formula of the Smo inhibitor is shown by a formula (I) as shown in the specification. The invention also discloses the synthesis method and the application of the Smo inhibitor. According to the invention, nilotinib is optimized into the dual-targeted inhibitor being active against Smo andBcr-Abl, and the inhibitor can overcome the tolerance problem caused by single-targeted drugs, has the advantages of improving anti-tumor efficacy and reducing toxic or side effects, and provides a reference for future research on dual-targeted anti-hematologic malignant drugs.